Acquisition Proposal Rejections, Court Rulings, Study Results, and Events Schedules - Analyst Notes on Allergan, Lilly, Amgen, Express Scripts and GSK

NEW YORK, May 16, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Allergan Inc. (NYSE: AGN), Eli Lilly & Co. (NYSE: LLY), Amgen Inc. (NASDAQ: AMGN), Express Scripts Inc. (NASDAQ: ESRX) and GlaxoSmithKline plc (NYSE: GSK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2533-100free.

--
Allergan Inc. Analyst Notes
On May 12, 2014, Allergan Inc. (Allergan) announced that its Board of Directors has unanimously rejected the unsolicited takeover bid made by Valeant Pharmaceuticals International Inc. (Valeant), saying the proposal substantially undervalues the Company while creating significant risks and uncertainties for the stockholders. Valeant had proposed to acquire all of the outstanding shares of Allergan for 0.83 shares of Valeant stock and $48.30 in cash. Besides, Allergan also announced that it expects to increase its EPS by 20-25% and continue to generate double digit revenue growth in 2015. The Company also expects to produce double digit sales growth and produce EPS compounded annual growth of 20% over the next five years. The full analyst notes on Allergan are available to download free of charge at:

http://www.analystsreview.com/2533-AGN-16May2014.pdf

--
Eli Lilly & Co. Analyst Notes
On May 9, 2014, Eli Lilly & Co. (Lilly) announced that a Brazilian Court has served the Company's local subsidiary, Eli Lilly do Brasil, with an approximately $450 million fine after investigations into a labor case alleging some employees were exposed to hazardous materials in a manufacturing facility operated by the Company between 1977 and 2003. The Company said that it would appeal this decision of the court as it is based on inaccurate scientific claims, as well as mathematical errors. According to Lilly, the alleged contaminants - benzene and heavy metals - were never used in the manufacturing operations at the facility. Michael J. Harrington, Senior Vice President and General Counsel for Lilly, commented, "In this case, there is absolutely no basis for the court's decision that employees were harmed based on extensive scientific and medical assessments conducted by third party health experts, as well as by Lilly." The full analyst notes on Lilly are available to download free of charge at:

http://www.analystsreview.com/2533-LLY-16May2014.pdf

--
Amgen Inc. Analyst Notes
On May 13, 2014, Amgen Inc. (Amgen) announced that the study of Phase 3 LAPLACE-2 has been published in the Journal of the American Medical Association (JAMA). The Company informed that the results from the 12-week study, which evaluated 1,896 patients with high cholesterol, showed treatment with subcutaneous evolocumab (140 mg every two weeks or 420 mg monthly) in combination with different daily doses of statin therapy significantly reduced mean low-density lipoprotein cholesterol (LDL-C) regardless of statin dose. Commenting on the development, Sean E. Harper, M.D., Executive Vice President of Research and Development at Amgen, said, "Results from the Phase 3 LAPLACE-2 study show that evolocumab provided cholesterol-lowering regardless of statin therapy and we look forward to bringing this new treatment option to patients who are taking statins and still need additional treatment options to lower their cholesterol levels." The full analyst notes on Amgen are available to download free of charge at:

http://www.analystsreview.com/2533-AMGN-16May2014.pdf

--
Express Scripts Inc. Analyst Notes
On May 5, 2014, Express Scripts Inc. (Express Scripts) announced that the Company will present at Jefferies 2014 Global Healthcare Conference scheduled to be held on Wednesday, June 4, 2014 at 8:00 a.m. ET. A webcast of the presentation will be available for access on Express Scripts' website. The full analyst notes on Express Scripts are available to download free of charge at:

http://www.analystsreview.com/2533-ESRX-16May2014.pdf

--
GlaxoSmithKline plc Analyst Notes
On May 13, 2014, GlaxoSmithKline plc (GSK) announced the headline results from its second phase III study with darapladib, SOLID-TIMI 52, evaluating the efficacy of its investigational Lp-PLA2 inhibitor in adults following an acute coronary syndrome. The Company informed that darapladib failed to achieve the primary endpoint of a reduction of major coronary events as compared to placebo when added to standard of care. However, the Company informed that the overall safety profile for darapladib showed no major safety concerns and was generally consistent with the safety data seen in the previously reported phase III study, STABILITY. The full analyst notes on GSK are available to download free of charge at:

http://www.analystsreview.com/2533-GSK-16May2014.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsReview.com

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED